Teva Argues Novartis SPC Invalid With Looming Drug Launch
Teva has denied that a generic drug it intends to launch in November would infringe on Novartis' intellectual property, asserting that the pharmaceutical giant will no longer be able to enjoy...To view the full article, register now.
Already a subscriber? Click here to view full article